Abstract:Ya-Hui Chen, 1, 2 Yi-Chun Chen, 1 Chi-Chen Lin, 3– 5 Yao-Peng Hsieh, 6– 8 Chien-Sheng Hsu, 9 Ming-Chia Hsieh 1, 10 1 Diabetes Research Laboratory, Department of Research, Changhua Christian Hospital, Changhua, Taiwan; 2 Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan; 3 Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan; 4 Department of Health and Nutrition, Asia University, Taichung, Taiwan; 5 Department of Medical Research, China Medical University Hospital, Taichung, Taiwan; 6 Division of General Internal Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 7 School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8 School of Medicine, Chung Shan Medical University, Taichung, Taiwan; 9 Frontier Molecular Medical Research Center in Children, Changhua Christian Children Hospital, Changhua, Taiwan; 10 Intelligent Diabetes Metabolism and Exercise Center, China Medical University Hospital, Taichung, Taiwan Correspondence: Ming-Chia Hsieh Email D94750@mail.cmuh.org.tw Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's chemotherapeutic initiation. Statins, including pitavastatin, have been indicated to have anticancer effects in numerous human cancer cell lines. Thus, in this study, we hypothesized that a combination of gemcitabine and pitavastatin may have a greater anticancer effect than gemcitabine alone on the human pancreatic carcinoma cell line MIA PaCa-2. Methods: The anticancer effects of gemcitabine with pitavastatin were evaluated using human MIA PaCa-2 cell line in vitro and in vivo Balb/c murine xenograft tumor model. Cell viability was assessed with CCK-8, and cell migration was stained by crystal violet. Cell cycle distribution, apoptosis and mitochondrial membrane potential were examined by flow cytometry. Activation of drug transporters (hENTs, hCNTs), intracellular drug activating (dCK) and inhibition of inactivating enzymes (RRMs) pathways were assessed by Western blotting analysis. Molecular mechanisms and signaling pathways of apoptosis, necrosis and autophagy also were assessed by Western blotting. Results: We observed that gemcitabine and pitavastatin synergistically suppressed the proliferation of MIA PaCa-2 cells through causing sub-G1 and S phase cell cycle arrest. Activation of apoptosis/necrosis was confirmed by annexin V/propidium iodide double staining, which showed increasing levels of active caspase 3, cleaved poly(ADP-ribose) polymerase and the RIP1–RIP3–MLKL complex. Moreover, gemcitabine–pitavastatin-mediated S phase arrest downregulated cyclin A2/CDK2 and upregulated p21/p27 in MIA PaCa-2 cells. Furthermore, this combination improved drug cellular metabolism pathway, mitochondria function and activated autophagy as part of the cell death mechanism. In vivo, gemcitabine-pitavastatin effectively inhibited tumor growth in a nude mouse mode of Mia PaCa-2 xenografts without observed adverse effect. Conclusion: Combined gemcitabine–pitavastatin may be an effective novel treatment option for pancreatic cancer. Keywords: synergistic anticancer, gemcitabine, pitavastatin, pancreatic cancer, MIA PaCa-2

Inhibitory Effect of Metformin Combined with Gemcitabine on Pancreatic Cancer Cells in Vitro and in Vivo.

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

An evaluation of the XR-10 intensifier in dental radiography.

HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Inhibition of Sirt1 Combined with Gemcitabine Therapy for Pancreatic Carcinoma

N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells

Combination therapy with interleukin-15 and metformin as a synergistic treatment for pancreatic cancer

Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer

Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer

Gemcitabine Induces Apoptosis and Autophagy Via the AMPK/mTOR Signaling Pathway in Pancreatic Cancer Cells

Effects of Gemcitabine on Radiosensitization, Apoptosis, and Bcl-2 and Bax Protein Expression in Human Pancreatic Cancer Xenografts in Nude Mice

Synergistic Anti-Tumor Effects of Liraglutide with Metformin on Pancreatic Cancer Cells

Effect of Sodium-Glucose Co-Transporter 2 Inhibitors Combined with Metformin on Pancreatic Cancer Cell Lines

Bisdemethoxycurcumin Potentiates Gemcitabine to Induce Mitochondrial Dysfunctions and Apoptosis in Human Pancreatic Adenocarcinoma Cells

[Efficacy of Gemcitabine-Based Chemotherapy on Advanced Pancreatic Cancer].

Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling

Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo